Abstract
The treatment of infections in critically ill obese and morbidly obese patients is challenging because of the combined physiological changes that result from obesity and critical illness. The aim of this study was to describe the population pharmacokinetics of piperacillin in a cohort of critically ill patients, including obese and morbidly obese patients. Critically ill patients who received piperacillin-tazobactam were classified according to their body mass index (BMI) as nonobese, obese, and morbidly obese. Plasma samples were collected, and piperacillin concentrations were determined by a validated chromatographic method. Population pharmacokinetic analysis and Monte Carlo dosing simulations were performed using Pmetrics software. Thirty-seven critically ill patients (including 12 obese patients and 12 morbidly obese patients) were enrolled. The patients' mean +/- standard deviation age, weight, and BMI were 50 +/- 15 years, 104 +/- 35 kg, and 38.0 +/- 15.0 kg/m(2), respectively. The concentration-time data were best described by a two-compartment linear model. The mean +/- SD parameter estimates for the final covariate model were a clearance of 14.0 +/- 7.1 liters/h, a volume of distribution of the central compartment of 49.0 +/- 19.0 liters, an intercompartmental clearance from the central compartment to the peripheral compartment of 0.9 +/- 0.6 liters . h(-1), and an intercompartmental clearance from the peripheral compartment to the central compartment of 2.3 +/- 2.8 liters . h(-1). A higher measured creatinine clearance and shorter-duration infusions were associated with a lower likelihood of achieving therapeutic piperacillin exposures in patients in all BMI categories. Piperacillin pharmacokinetics are altered in the presence of obesity and critical illness. As with nonobese patients, prolonged infusions increase the likelihood of achieving therapeutic concentrations.